2888 - Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, ≥12 Years of Age

Presenting Author(s)

• JR

  Jason S. Richardson, PhD

  Director, Clinical Research
  Bavarian Nordic
  Winnipeg, MB, Canada

  Slides

Co-Author(s)

• DA

  Debbie Anderson, MS

  Bavarian Nordic
  Victoria, British Columbia, Canada
• JM

  Jason Mendy, MS

  Bavarian Nordic
  San Diego, California, United States
• SM

  Sufia Muhammad, MD

  Bavarian Nordic
  San Diego, California, United States
• LT

  Lauren Tindale, PhD

  Scientist
  Bavarian Nordic
  Vancouver, British Columbia, Canada
• TL

  Tobi Loreth, n/a

  Bavarian Nordic
  Winnipeg, Manitoba, Canada
• SR

  Sarah Royalty Tredo, MBA

  Emergent Biosolutions
  Mclean, Virginia, United States
• VJ

  Victoria Jenkins, PhD

  Bavarian Nordic
  Zug, Zug, Switzerland
• PA

  Patrick Ajiboye, MD

  Bavarian Nordic
  Ellicott City, Maryland, United States
• LB

  Lisa Bedell, Director Biostatistic

  Director Biostatistic
  Emergent Biosolutions
  Gaithersburg, Maryland, United States